Eosinophilic Chronic Rhinosinusitis — Study of Benralizumab (KHK4563) in Patients With Eosinophilic Chronic Rhinosinusitis
Citation(s)
A Phase 2, Double-Blind, Placebo-Controlled Study of Benralizumab (KHK4563) in Patients With Eosinophilic Chronic Rhinosinusitis